People · Operator

Douglas M. Karp

Named in public records as an officer, director or promoter · active 2009–2010 · Pharmaceuticals

2
Companies
5
Filings
$55.8M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Nautilus Neurosciences, Inc.PharmaceuticalsSeries B$53.3M$272.0M2009
Vpi Holdings CorpPharmaceuticalsSeed$2.5M$95.1M2009
Operator network

Douglas M. Karp at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Frank V Sica · 3 companies · 1 sharedFrank V SicaDavid V. Azad · 1 companies · 1 sharedDavid V. AzadEric J. Liebler · 1 companies · 1 sharedEric J. LieblerJames L. Fares · 1 companies · 1 sharedJames L. FaresJohn V. Groom · 1 companies · 1 sharedJohn V. GroomNeil R. Milano · 1 companies · 1 sharedNeil R. MilanoWilliam R. Maichle · 1 companies · 1 sharedWilliam R. MaichleWilliam V. Maichle · 1 companies · 1 sharedWilliam V. MaichleZubeen V. Shroff · 1 companies · 1 sharedZubeen V. ShroffGeoffrey S. Raker · 6 companies · 2 sharedGeoffrey S. RakerJoseph W. Leary · 1 companies · 1 sharedJoseph W. LearyKevin Connelly · 1 companies · 1 sharedKevin ConnellyStephen M. McCune · 1 companies · 1 sharedStephen M. McCuneNautilus Neurosciences, Inc. · $53.3M raisedNautilus Neuroscience…Vpi Holdings Corp · $2.5M raisedVpi Holdings CorpDouglas M. KarpDK
Douglas M. Karp Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Douglas M. Karp on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Geoffrey S. Raker26
Frank V Sica13
James L. Fares11
William R. Maichle11
Neil R. Milano11
William V. Maichle11
David V. Azad11
Zubeen V. Shroff11
John V. Groom11
Joseph W. Leary11
Kevin Connelly11
Stephen M. McCune11
Eric J. Liebler11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.